Publication:
Upfront frameless hypofractionated gamma knife radiosurgery for large posterior Fossa metastases

dc.contributor.departmentSchool of Medicine
dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.kuauthorFaculty Member, Samancı, Mustafa Yavuz
dc.contributor.kuauthorUndergraduate Student, Aydın, Serhat
dc.contributor.kuauthorDoctor, Düzkalır, Ali Haluk
dc.contributor.kuauthorOther, Askeroğlu, Mehmet Orbay
dc.contributor.kuauthorFaculty Member, Peker, Selçuk
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.date.accessioned2025-09-10T04:55:26Z
dc.date.available2025-09-09
dc.date.issued2025
dc.description.abstractThe management of large metastatic brain tumors (METs), particularly those in the posterior fossa (pf-METs), is challenging. While surgery can alleviate symptoms, it carries the risk of complications such as leptomeningeal disease (LMD). Upfront hypofractionated Gamma Knife radiosurgery (hf-GKRS) has shown promise as an alternative approach for managing large METs. This study assesses the efficacy and safety of upfront hf-GKRS for treatment-na & iuml;ve large pf-METs. In this retrospective, single-center study, 40 patients with 42 pf-METs received hf-GKRS from October 2017 to June 2024. Patients eligible for the study were 18 years or older, had histologically confirmed malignancy, large pf-METs (> 4 cm(3)), and a minimum of two follow-up MRI scans. The primary outcome was local control (LC), with secondary assessments of distant intracranial failure (DICF), intracranial progression-free survival (PFS), overall survival (OS), and toxicity. LC was achieved in 88.1% of pf-METs over a median follow-up of 6 months (mean: 13.7 months). LC rates at 6, 12, and 24 months were 95.8%, 95.8%, and 74.5%, respectively. Local failure (LF) occurred in 11.9% of cases, with a median recurrence time of 12 months. DICF was noted in 35% of patients, while no cases of LMD were reported. Intracranial PFS rates at 6, 12, and 24 months were 54.1%, 39.0%, and 16.7%, respectively, with a median PFS of 8 months. Symptomatic hydrocephalus developed in one patient (2.5%). Controlled primary tumor status (HR: 0.17, p = 0.036) was significantly associated with lower risk of death, while no other parameters were predictive of LC, DICF, or intracranial PFS. hf-GKRS demonstrates strong efficacy and safety as a primary treatment for selected, treatment-na & iuml;ve large pf-METs over a relatively short follow-up duration. Further studies are warranted to refine patient selection, fractionation, and dosing strategies for this challenging population.
dc.description.fulltextYes
dc.description.harvestedfromManual
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.openaccessGold OA
dc.description.publisherscopeInternational
dc.description.readpublishN/A
dc.description.sponsoredbyTubitakEuTÜBİTAK
dc.description.sponsorshipScientific and Technological Research Council of Turkiye (TUEBITAK)
dc.description.versionPublished Version
dc.description.volume48
dc.identifier.doi10.1007/s10143-025-03572-4
dc.identifier.eissn1437-2320
dc.identifier.embargoNo
dc.identifier.filenameinventorynoIR06355
dc.identifier.issn0344-5607
dc.identifier.issue1
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-105005270908
dc.identifier.urihttps://doi.org/10.1007/s10143-025-03572-4
dc.identifier.urihttps://hdl.handle.net/20.500.14288/30075
dc.identifier.wos001489433000002
dc.keywordsHypofractionation
dc.keywordsGamma knife radiosurgery
dc.keywordsMetastatic brain tumors
dc.keywordsPosterior fossa
dc.keywordsUpfront radiosurgery
dc.language.isoeng
dc.publisherSpringer
dc.relation.affiliationKoç University
dc.relation.collectionKoç University Institutional Repository
dc.relation.ispartofNeurosurgical Review
dc.relation.openaccessYes
dc.rightsCC BY (Attribution)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectClinical neurology
dc.subjectSurgery
dc.titleUpfront frameless hypofractionated gamma knife radiosurgery for large posterior Fossa metastases
dc.typeJournal Article
dspace.entity.typePublication
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
IR06355.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format